Brain-Computer Interfaces Brief, Jul 25

01Overview

BCIs moved through demonstrations, money and conditions of use, and no implanted device gained new market access

Between Jul 25 and Oct 23, 2026, regulators changed what an investigational system may connect to, how brain data must be prepared and how a BCI procedure is coded, not who may sell. Statuses are judged against Oct 24, 2026.

Five conclusions of the quarter

Speech moved into human use, but the evidence is single-participant and company-reported

Paradromics said on Sep 14, 2026 that its first Connect-One participant had a free sentence decoded in real time with no errors: one sentence, with no published error rate (company press release). Neuralink posted a video on Sep 16, 2026 of the third VOICE participant (NCT07224256) speaking with a synthesised voice; no peer-reviewed accuracy or latency benchmark exists.

Paradromics · Sep 14, 2026 · company press releaseNeuralink VOICE · Sep 16, 2026 · company videoNeuralink PRIME · 21 participants, zero serious device-related adverse events · Jan 28, 2026 · company-reportedSynchron SWITCH · 4 participants, 12 months, no serious adverse event · JAMA Neurology, 2023 (context)

Open the trial evidence (module 2)

Regulators changed the conditions of use, not market access

The FDA letter of Aug 26, 2026 lets Paradromics add compatible laptops, tablets and phones to its investigational system without per-device approval (company-announced). CorTec reports a second Breakthrough Device Designation, granted in August 2026 (company-reported); a designation is not an approval. In China, Neuracle's NEO sold 13 units at 475,000 yuan, 13 × 475,000 = 6.175 million yuan, and sits in no insurance catalogue (reported, Sep 29, 2026 filing). CMS comments on a Neuralink coding request closed on Oct 16, 2026.

FDA letter · Aug 26, 2026 · company-announcedCorTec designation · Aug 2026 · company-reportedNEO · 13 units · Sep 29, 2026 filing · reportedCMS code request · comments closed Oct 16, 2026 · under consideration

Open the approvals (module 3)

Durability and scale claims are real but not comparable

Paradromics reported stable recording for more than four years in two sheep, plotted at days 1,470 and 1,443 (company-reported, Oct 8, 2026). CorTec reported 63 of 64 contacts working in macaques, with data to day 1,361, 3.7 years (company-reported, Oct 21, 2026). Precision's preprint atlas covers 70 patients and over 180 hours. Different species, tasks and criteria mean none of these can be ranked against another.

Paradromics · pure tones, auditory cortexCorTec · visual-motor taskPrecision · device cleared only for temporary useNeuralink · 50,000+ hours of human recordings · Oct 1, 2026 · company-reportedSynchron · 16-electrode Stentrode: clicks and menu selection

Open the technical routes (module 4)

Money followed the field, and trackers disagree on its size

Precision announced a $250M Series D on Sep 24, 2026, bringing total capital to $430M (announced). One tracker counts 72 BCI financings since January 2024, 44 of them Chinese and 18 American, yet the US took 63.4% of capital (tracker estimate, Oct 6, 2026). Four trackers range from $1.63B to $4.95B because they count different things. Neuracle's RMB 2.5bn STAR Market application is pending (filed Sep 29, 2026) against 6.175 million yuan of cumulative NEO sales. Gestala's two rounds total RMB 570M, about $84M (company release).

Precision · $250M · Sep 24, 2026 · announcedTracker · 72 financings · Oct 6, 2026 · tracker estimateTrackers · $1.63B to $4.95B · different scopesGestala · RMB 570M · Mar and Jul 2026 · company release

Open funding and companies (module 5)

Rules are moving on data, while implant safety evidence stays thin

A Communications Medicine review published Jul 27, 2026 names five gaps in implantable-BCI data protection. The US MIND Act, a proposed FTC study of neural data, was still awaiting committee action on Oct 16, 2026. The only implant safety count in the material is the developer's own: zero serious device-related adverse events among 21 participants (Neuralink, company-reported, Jan 28, 2026). The Australian Human Rights Commission found that 24 of 30 consumer neurotechnology companies had policies allowing potential sale of neural data (date not stated).

Review · 5 gaps · Jul 27, 2026 · publishedMIND Act · Oct 16, 2026 · awaiting committeeNeuralink · 0 serious events, 21 participants · Jan 28, 2026 · company-reported

Open ethics and safety (module 6)

Programmes at a glance

Programme	Route	Stage	Latest milestone	Date	Basis	Source
NeuralinkN1 (PRIME; VOICE NCT07224256)	Intracortical	Human trials	Third VOICE participant speech video	Sep 16, 2026	Company video, not peer-reviewed	Yahoo Tech; explainx
ParadromicsConnexus (Connect-One NCT07357428)	Intracortical	Early feasibility, 1 of up to 10 implanted	Free sentence decoded in real time	Sep 14, 2026	Company-reported	Paradromics
SynchronStentrode (INTENT NCT07543367)	Endovascular	10 planned, recruiting	Registered	Apr 2026	Registry	BCI Briefing
Precision NeuroscienceLayer 7	Surface ECoG	Cleared for up to 30 days; 100+ procedures	$250M Series D	Sep 24, 2026	Announced	MedTech Dive; Neurofounders
CorTecBrain Interchange	Surface, wireless	Stroke study, 3 patients	Second Breakthrough designation	Aug 2026 (per company)	Granted, company-reported	CorTec via EQS
NeuracleNEO	Implanted (route not stated)	NMPA Class III registered Mar 13, 2026	13 units sold, 8 implanted	Sep 29, 2026 filing	Reported	BigGo Finance
Merge LabsPoseidon ultrasound-on-chip (licensed)	Ultrasound	No human data	Butterfly licence signed	Sep 1, 2026	Announced	Butterfly Network
Bridge NeurotechUltrasound-on-chip (licensed)	Ultrasound, non-invasive	First human study enrolling	Butterfly licence; $13.5M launch round	Oct 6, 2026	Reported	Startup Fortune; New Market Pitch

Each row shows its basis label and date; a milestone is not an approval.

02Clinical trial progress

Speech reached human participants, but the two headline speech results are single-participant company demonstrations

Who was implanted, under which identifier, and what was measured. Figures keep their basis label; none is compared across different tasks.

Trial scoreboard

Programme	Key figure	Date	Basis	Source
Neuralink PRIMEN1, intracortical; identifier not in the material	21 participants; zero serious device-related adverse events	Jan 28, 2026	Company-reported	Neura Pod (via Neuralink)
Neuralink VOICEN1; NCT07224256; ALS, PLS, stroke, spinal cord injury	Third participant spoke with a synthesised voice	Video Sep 16, 2026	Company video, not peer-reviewed	Yahoo Tech; explainx
Paradromics Connect-OneConnexus, intracortical, 421 microelectrodes; NCT07357428	1 implanted (June); up to 10 planned, ages 22 to 75, 3 sites	Sep 14, 2026	Company press release	Paradromics; ALS News Today
Synchron INTENTStentrode, endovascular, 16 electrodes; NCT07543367	10 planned, 5 US sites	Registered Apr 2026	Registry, recruiting	BCI Briefing
Synchron COMMAND and SWITCHNCT05035823 and NCT03834857	6 and 5 participants	COMMAND completion Sep 19, 2024	RegistrySWITCH peer-reviewed (JAMA Neurology, 2023)	BCI Briefing
Precision Layer 7Surface ECoG, 1,024 channels	More than 100 procedures, 18 institutions	Sep 2026	Company-reported	Neural Noise; Neurofounders
CorTec Brain InterchangeSurface, wireless	3 stroke patients (NCT06506279); 13 epilepsy patients (NCT05439655)	Oct 21, 2026	Company-reported	CorTec (via TradingView)
UCSF ECoG avatar study	3 participants; 2 drove a full-body avatar	Sep 14, 2026	Peer-reviewed	NIH (via Medical Xpress); Nature Neuroscience
StairMed WISENCT07647315	Recruiting, Huashan Hospital	Listed Sep 1, 2026	Registry	BCI Briefing

Programme detail

NeuralinkCompany-reported

The latest company-stated count is 21 participants on Jan 28, 2026 (company-reported). A Neura Pod tally of 27+ in October is a third-party count, not Neuralink's. New Market Pitch (Sep 8) puts the count seven months earlier at five, a jump of 21 − 5 = 16.

VOICE is the newer study: a 23-second video on Sep 16, 2026. A later full video identified the participant as the third VOICE participant, who has bulbar-onset ALS and can still move. According to Yahoo Tech, Neuralink has published no peer-reviewed accuracy or latency benchmark for VOICE.

ParadromicsCompany press release

The first Connexus implant was placed in June 2026 at the University of Michigan. On Sep 14, 2026 the company said its participant, a woman in her 60s with motor neuron disease, chose her own words, answered open-ended questions and held a phone call, and that her first free sentence was decoded in real time with no errors. That is one sentence, with no published error rate.

The study runs under an IDE granted in November 2025 and has three sites: UC Davis, Mass General Brigham and Michigan.

Scale of the speech evidence

10%of planned enrolment implanted: 1 ÷ 10 Paradromics participants (company press release, Sep 14, 2026)

50,000+ hof human neural recordings reported by Neuralink in an Oct 1, 2026 update (company-reported)

0peer-reviewed accuracy figures for either headline speech result

Synchron registered participantsRegistry

Registered participants add up to 10 + 6 + 5 = 21 across INTENT, COMMAND and SWITCH, matching the briefing's total (registry). SWITCH is the only peer-reviewed set: four implanted participants completed 12 months with no serious adverse event, vessel occlusion or device migration (JAMA Neurology, 2023).

The registry lists five SWITCH participants against four in the paper; the material does not explain the gap.

Pivotal trial and sources in conflictReported

A pivotal trial is described as planned for 2026 (reported, not a company filing in this material). One source speaks of 100-patient cohorts at Synchron, which the registry data do not support; the page follows the registry.

Synchron has the best-documented safety record but the smallest recent news flow.

PrecisionPreprint

Counts procedures, not chronic users: more than 100 procedures at 18 institutions (company-reported). Its website claimed more than 95 clinical-study patients on Sep 8. Many are temporary placements during neurosurgery already needed, and the clearance allows up to 30 days.

A preprint reports 70 patients at 12 centres, over 180 hours of recordings and finger representations resolved at 0.8 mm; it is a preprint with company-collected data.

CorTecCompany-reported

Three stroke patients (NCT06506279) and 13 epilepsy patients (NCT05439655), reported Oct 21, 2026 (company-reported). The first stroke participant had the system removed after nine months, as the protocol planned.

Blackrock NeurotechContext

No sponsor milestone in the material. Its Utah Array, first placed in a human in 2004, underlies most BCI trials to date. The BrainGate consortium listed a Current Biology paper online on Aug 11, 2026 (array maker not stated).

China registry countRegistry

ClinicalTrials.gov lists 21 open studies with a Chinese site, 11 of them implanted, as of Oct 19, 2026. That register under-counts studies outside the United States.

StairMed and NeuracleRegistry

StairMed has four registered studies, including WISE and a spinal-cord-injury study (NCT07603752, Apr 28, 2026), both at Huashan Hospital. Neuracle's NEO study (NCT06990412) is marked completed; its approval is in module 3. NeuCyber's Beinao implants appear only as a programme, with no identifier or participant count.

Bridge NeurotechReported

Opened a first non-invasive ultrasound study on Oct 6, 2026, without a published identifier.

Outcome measures do not line up

Neuralink cites bits per second on cursor tasks (a record of 11.32 in 2026, company-reported). Paradromics cites error-free decoding of one free sentence (company press release, Sep 14, 2026). Synchron's 16-electrode device has yielded clicks and menu selection. None of these can be ranked against another.

03Regulatory approvals

Regulators widened what trial devices may do, but a designation, a code request or a standard is not an approval

Between Jul 25 and Oct 23, 2026 the material shows no new marketing authorisation for an implanted BCI. Regulators moved on conditions of use. Statuses are judged against Oct 24, 2026.

0No implanted BCI gained new market access in the window: one FDA letter widened what a trial device may connect to, one extra Breakthrough designation was reported, and China's data standard is due Sep 1, 2027.

Regulatory items

Item	Key figure	Date	Status (as of Oct 24, 2026)	Source
FDA approval letter, Paradromics Connect-OneConvey on personal devices	Laptops, tablets, phones addable without per-device approval	Aug 26, 2026	In effect for the investigational studyCompany-announced	Paradromics (via Business Wire)
FDA Breakthrough Device Designation, CorTec Brain Interchangecommunication	Second designation; non-progressive quadriplegia, cursor control	Aug 2026 per company; reported Sep 18	GrantedCompany-reported	CorTec (via EQS); Robotics & Automation News
NMPA industry standardEEG datasets used by AI in BCI devices	Covers 5 data stages; effective Sep 1, 2027	Issued mid-Sep 2026	Issued; takes effect 2027	TechTimes; Neurofounders
NEO (Neuracle) commercial uptakeafter NMPA registration	13 units sold, 8 implants, 475,000 yuan list price	First sale Jul 2026; data from Sep 29 filing	Reported	BigGo Finance
CMS ICD-10-PCS requestInsertion of Brain Computer Interface Device (Neuralink)	Requested start Apr 1, 2027; NTAP application intended	Comments closed Oct 16, 2026	Under consideration	CMS
CMS RAPID coverage pathwayfor breakthrough devices	AdvaMed comment letter	Date not stated	Proposed	AdvaMed

By jurisdiction

Paradromics letter, Aug 26Company-announced

The FDA issued an approval letter expanding the computing devices usable with the investigational Connexus BCI (company-announced). Once an agreed deployment and testing process is followed, compatible devices can be added to Convey without approval for each new device. It is a change to an investigational study, not a market authorisation. The IDE was granted in November 2025 (context). No FDA document is in the material.

CorTec designationCompany-reported

Second Breakthrough Device Designation, for cursor control by people with non-progressive quadriplegia; the first (April 2026, stroke rehabilitation) is context. CorTec's Oct 21 release says August; a trade report is dated Sep 18. The page follows the company's month and treats the exact date as not stated.

A designation is not an approvalReported

The FDA says the programme speeds development and review, gives prioritised interaction, and still requires the same safety and effectiveness standards; a decision on a request comes within 60 calendar days. Neurotech Reports says the FDA has no BCI-specific pathway and the best-case US timeline averages just over 300 days, nearly double China's fast track (reported).

Context: Precision Layer 7 holds FDA clearance for up to 30 days of use (March 2025), with further FDA review pending. According to Exoswan, the FDA said in August 2026 that NeuroPace's NAUTILUS submission for its RNS System was not approvable in its current form.

From registration to purchase list, per dated reportingContext, before the window

Mar 13, 2026NMPA Class III registration for NEO, adults aged 18 to 60 with C2 to C6 spinal cord injury

Mar 22National insurance consumable code

Mar 23Shanghai catalogue entry

Mar 24Procurement listing, 11 days after registration (BioSpectrum sequence; other outlets say the code came within 48 hours)

Jul 2026First commercial sale; 13 units sold, 8 implanted, over 70 intended orders (Sep 29, 2026 STAR Market prospectus, reported)

A code is not coverage

6.175M yuancumulative NEO sales: 13 × 475,000 yuan list price (reported, Sep 29, 2026 filing)

142,500 yuanShanghai Huhuibao scheme: 0.30 × 475,000, under the 150,000 yuan annual cap, before surgery and rehabilitation costs

Sep 1, 2027NMPA EEG-dataset standard takes effect (announced; issued mid-Sep 2026)

NEO is in neither the national nor local basic insurance catalogues. A national BCI reference architecture took effect Aug 1, 2026, and a MIIT draft roadmap targets more than 40 BCI standards by 2028 and more than 80 by 2030 (draft). NHSA's guided price of 6,000 to 6,600 yuan per implantation procedure (April 2026, context) is a procedure price, not a device price.

CMS code requestUnder consideration

CMS lists a Neuralink request for an ICD-10-PCS code, Insertion of Brain Computer Interface Device, for an Apr 1, 2027 start, with the requestor intending to file for a New Technology Add-on Payment later. The comment deadline of Oct 16, 2026 has passed. A code request does not create coverage.

RAPID pathwayProposed

Meant to align FDA authorisation with Medicare coverage for breakthrough devices. Neurotech Reports describes it as announced jointly by CMS and FDA, but AdvaMed calls it proposed, with industry comments pending. The page follows AdvaMed. No RAPID date or BCI-specific coverage decision is in the material.

Europe and other regulatorsContext

In Europe, medical BCIs fall under the Medical Device Regulation. The only EU authorisation in the material is Science Corporation's PRIMA retinal implant, CE-marked and launched on Jul 22, 2026, three days before the window (context). The UK MHRA approval of Neuralink's GB-PRIME trial and a Canadian allowance for six participants are reported without dates.

04Technical routes compared

Durability and scale claims stand as separate results because tasks, species and criteria differ

What the devices measured in the window, who measured it, and which numbers can sit side by side. No route has a decoding number this quarter that is both peer-reviewed and comparable across devices.

Route scorecard

Item (route)	Key figure	Date	Basis	Source
Paradromics Connexusintracortical	Stable spike SNR, 2 sheep, days 1,470 and 1,443	Oct 8, 2026	Company-reported, preclinical	Paradromics; MassDevice
Connexus full device, 6 sheep	About 80% decoding vs 14.3% chance; 6,100+ active hours	Oct 2026, day not stated	Company-reported	Neurofounders
Neuralink N1intracortical	Cursor record 11.32 bits/s; 50,000+ h recorded	Oct 1, 2026 update	Company-reported	Neurofounders; Neura Pod
Neuralink VOICENCT07224256	Speech video; no peer-reviewed benchmark	Sep 16, 2026 (full video Sep 19)	Company video	Yahoo Tech; explainx
Precision Layer 7surface, up to 1,024 channels	Atlas: 180+ h, 70 patients, 87,000+ microelectrodes	Oct 2026, day not stated	Preprint	Neurofounders
CorTec electrodessurface µECoG, NCT06506279	63 of 64 contacts working after 4+ years, macaque	Oct 21, 2026	Peer-reviewed proceedings	CorTec (via TradingView)
Synchron Stentrodeendovascular, 16 electrodes	Clicks and menu selection only	Profile checked Oct 3, 2026	Secondary profile	BCI Briefing
Merge Labsultrasound	Butterfly ultrasound-on-chip licence; no human data	Sep 1, 2026	Announced	Butterfly Network
Bridge Neurotechultrasound	Butterfly licence; first human study enrolling	Oct 6, 2026	Reported	Startup Fortune
EEG imagined-speech baseline	49.03 ± 4.18% cross-subject, coarse classification	Week of Sep 21, 2026	Preprint	Neural Noise

The two four-year durability claims

Both are company-reported and both are about four years. Open the comparison to see why they are not a ranking.

Paradromics, sheepCompany-reported

Basis: company-reported, Oct 8, 2026, preclinical.

Result: stable recording for more than four years in two sheep; data points at day 1,470 (1,470 ÷ 365.25 = 4.0 years) and day 1,443 (3.95 years).

Task and criterion: pure tones in auditory cortex; electrodes 40 µm wide reaching 1.5 mm deep; no electrode migration.

CorTec, macaquePeer-reviewed proceedings

Basis: company-reported, Oct 21, 2026, published in the Graz BCI Conference proceedings.

Result: 63 of 64 contacts still working in two macaques, analysed to day 1,361 (1,361 ÷ 365.25 = 3.7 years); one contact failed at about 14 months.

Task and criterion: visual-motor reaction task; usable signal and alert-versus-drowsy contrast.

Not a ranking: different animal, route and criterion. Paradromics also says its spike SNR (above 5) beats published Utah array values of 1.5 to 4 in macaque motor cortex; that compares species, cortex and analysis, so this page does not use it.

Reading the scale numbers

≈1,243

microelectrodes per patient in Precision's atlas: 87,000 ÷ 70 (preprint, Oct 2026)

≈2.6 h

recorded per patient: 180 ÷ 70, from a device cleared only for temporary use (preprint)

64×

fewer electrodes in Synchron's 16-electrode Stentrode than 1,024 (secondary profile)

≈278×

more hours in Neuralink's 50,000 than Precision's 180, but from chronic implants, so a different thing (company-reported)

Derived values: these are our arithmetic on the reported figures, not published rates. The hours gap compares different devices and is shown for scale only.

Ultrasound and non-invasive

Mostly pre-human numbersAnnounced

Butterfly Network announced a multi-year licence for Merge Labs on Sep 1, 2026; Bridge Neurotech announced a similar licence and a first human study on Oct 6. Neither has published a decoding number. Gestala's first product is still in development and clinical preparation.

Ultrasound reads blood flow, not spikesSecondary

A Tencent News explainer (Aug 21, 2026) says the monkey decoder ran on 2 Hz images, one frame every 0.5 s, so the ceiling is vascular lag, not hardware. Chinese company claims of 1.5 mm focusing and under 1 mm over 57 cases are company or secondary claims.

EEG is further backPreprint

The imagined-speech baseline reached 49.03 ± 4.18% on coarse classes; EEGNet under attack stayed near 22 to 24%. Both are preprints and are called baselines, not solved communication.

=Compare like with like. The same BEST decoder scored a 6.19% word error rate on Brain-to-Text 2024 and 1.62% on 2025, a 3.8-fold gap (6.19 ÷ 1.62) from the benchmark alone (arXiv preprint). Compare only the same task, vocabulary, species and measurer; Neuralink's 11.32 bits/s is a cursor figure that says nothing about speech.

05Funding and companies

China led on deal count and the US on dollars, and tracker totals cannot be added together

Where the money went, from Precision's $250 million round to China's IPO queue. Amounts keep their basis label; dates are judged against Oct 24, 2026.

BCI financings per period

Tracker estimate (New Market Pitch BCI tracker, Oct 6, 2026): deals rose from 10 (2024) to 21 (2025) to 41 (first nine months of 2026), and 10 + 21 + 41 = 72.

China led on deal count, the US on dollars

44 vs 18Chinese vs American financings among the 72 since January 2024 (tracker estimate)

63.4%of measured capital taken by the US (tracker estimate, Oct 6, 2026)

$20.8M / $56.3Mmedian and average round; 2,816 ÷ 56.3 ≈ 50 rounds with a disclosed amount

Rounds, China and trackers

Item	Key figure	Date	Basis	Source
Precision Neuroscience Series D	$250M; total raised $430M	Sep 24, 2026	Announced (company, via press)	MedTech Dive; Fierce Biotech
Bridge Neurotech launch round	$13.5M	Oct 6, 2026	Reported	New Market Pitch
BCI-Sonics Pre-A	RMB 200M (~$28M)	Sep 22, 2026	Reported	Neurofounders
Merge Labs seedcontext	$252M; Butterfly licence signed Sep 1	Jan 2026; Sep 1	Company statement	Business Wire
Neuralink last priced round	$650M Series E; no new round in window	2025	Last disclosed	Investing in the Web
Gestala, two rounds	RMB 570M (~$84M)	Mar and Jul 2026	Company release	PRNewswire via Yahoo Finance
Neuracle STAR Market IPO	Raise RMB 2.5bn; updated prospectus Sep 29	Sep 29, 2026	Filed, pending	BigGo Finance

Precision and the US pictureAnnounced

Announced Thursday, Sep 24, 2026; later dates in the press (Sep 25 to Oct 9) are coverage dates. Co-led by Pershing Square, the Ackman Oxman Institute and an undisclosed life-sciences fund. Total funding is $430M, so earlier capital was 430 − 250 = $180M. Proceeds go to the clinical programme, further FDA review of Layer 7 and commercial infrastructure.

Only Tech Funding News gives a valuation, just over $1 billion (press-reported, single source). A tracker lists about $467M total against the company's $430M; the page follows $430M.

Neuralink and Merge LabsEstimates, not transactions

Neuralink announced no new priced round in the window; its last disclosed round is the mid-2025 Series E of $650M, with post-money $9.0B + $0.65B = $9.65B. Higher figures of $29–42B, $24–29B and $25–32B are estimates from secondary-market activity, not transaction prices; no IPO has been announced.

Merge Labs launched in January 2026 with a $252M seed from OpenAI, Bain Capital, Interface Fund, Fifty Years and Gabe Newell (context), and signed its Butterfly licence on Sep 1, 2026; amounts undisclosed.

Rounds in the windowReported

BCI-Sonics raised RMB 200M (Pre-A, Sep 22, led by Sequoia China and Yunqi Capital; about 7.1 RMB per dollar against the ~$28M reported). GenLight announced consecutive Series C and D rounds of several hundred million RMB in September. Active Technology (~$46M Angel, Aug 3) and Mindtrix (August) are further large rounds.

GestalaCompany release

RMB 150M (March) plus RMB 420M (July), 150 + 420 = RMB 570M, about $84M (company release). The RMB 420M Angel+ was announced on Jul 3, three weeks before the window. Gestala plans a first-generation ultrasound system and initial clinical data by end-2026 (plan, not delivered).

Listings are the new channelPending

Shuli Innovation entered STAR Market IPO counselling on Sep 4. Neuracle's RMB 2.5bn STAR application was accepted in June; cumulative NEO sales were 13 × RMB 475,000 = RMB 6.175M, about 0.25% of the target (reported, Sep 29, 2026 filing). BrainCo reportedly filed confidentially in Hong Kong (Bloomberg, via Neurofounders).

Labels conflict across trackers: one calls BCI-Sonics a Seed, and Mindtrix is $49M or $52M. The page follows the sources that say Pre-A and shows both Mindtrix figures. For H1 2026, Neurofounders counted 34 Chinese BCI financings with disclosed funding above RMB 4bn.

Four trackers give totals from $1.63B to $4.95B because they count different things, so their totals cannot be added or compared.

Tracker (date)	Scope and definition	Count	Amount	Basis
New Market Pitch BCIOct 6	Brain activity to commands: invasive, non-invasive, decoding software, interface hardware; excludes imaging and muscle-controlled interfaces; since Jan 2024	72 financings, 55 companies	$2.816B	Tracker estimate
New Market Pitch neurotechSep 14	All neurotechnology; BCI is 31.4% of deals	204 deals	$4.95B	Tracker estimate
Neurofounders H1Aug 9; revised Aug 13	363 Startup Map companies; includes grants, debt, public-market deals	81 events (revised 82)	$2.64B (revised $2.66B)	Tracker estimate
New Market Pitch pure-playJul 13	Equity rounds ≥ $300K, Aug 2025 to Jul 2026	26 deals	$1.63B	Tracker estimate

They do not reconcile: 31.4% × 204 ≈ 64 BCI deals in one tracker, against 72 in the BCI tracker from the same publisher. Neurofounders' H1 BCI total was about $690M, of which Merge Labs and Science made 252 + 230 = $482M, about 70%. Trackers are secondary estimates: use them for trend, not as audited totals.

06Ethics and safety

Rules are moving on neural data while implant safety evidence stays thin and mostly company-reported

What the same devices do to the data and people they touch, and which rules and safety evidence existed on Oct 24, 2026.

!Neural-data rules multiplied during the quarter, but the only implant safety figure in the material is the developer's own: 0 serious device-related adverse events among 21 participants, reported Jan 28, 2026 and not independently confirmed.

Items in the window

Item	Key figure	Date	Status	Source
iBCI data-protection review	5 gaps	Jul 27, 2026	Published	Communications Medicine
OECD Paper No. 195, Neurodata governance	16 companies mapped	04/09/2026 (as printed)	Published	OECD
NMPA AI-BCI EEG data standard	Effective Sept 1, 2027	Mid-Sept 2026	Issued, not in effect	According to TechTimes
California AB 1883	Assembly passed in May	Aug 19, 2026	Pending	Bloomberg Law
US MIND Act (S.2925)	FTC study	Oct 16, 2026	Awaiting committee	The Transmitter
Neuralink safety record	0 serious adverse events, 21 participants	Jan 28, 2026	Company-reported	Neura Pod

Law, data rights and safety evidence

US states, a patchworkOpinion piece, The Transmitter, Oct 16, 2026

State	What it did
California	Amended its privacy act to define brain data by its origin in the nervous system; excludes data inferred from non-neural information. Classed neural data as sensitive personal information in 2024.
Colorado	Amended its privacy act to define brain data by origin in the nervous system; does not exclude inferred data.
Connecticut	Added neurodata to its sensitive-data list; covers only the central nervous system.
Montana	Folded neurotechnology data into its Genetic Information Privacy Act; excludes pupil dilation and breathing rate.

CalMatters says Alabama, Illinois, New York, Vermont and Virginia were considering bills in 2026. AB 1883 would bar, with exceptions, employer use of surveillance tools that collect neural data; the Senate was still considering it on Aug 19, 2026.

Federal and internationalPending

The MIND Act, introduced Sept 24, 2025 by Senators Schumer, Cantwell and Markey, would direct the FTC to study neural data for a year; it was still awaiting committee action on Oct 16, 2026. UNESCO member states adopted a neurotechnology ethics recommendation in November 2025. The OECD paper warns that overlapping neurodata frameworks make compliance hard.

The commercial risk is documented

24 of 30consumer neurotechnology companies (80%) had policies allowing potential sale of neural data (Australian Human Rights Commission, date not stated)

Two analyses argue the definition fight is a distraction and favour regulating outcomes of data use over data origin.

Five gaps in implantable-BCI data protectionPublished

The Communications Medicine review (Jul 27, 2026) finds iBCI data under-protected despite HIPAA and GDPR. The gaps: reliance on conventional de-identification, limited individual control, conflated consent, weak misuse guardrails and unclear ownership.

Remedies are proposals, not rulesProposal

Separate data consent and limits on secondary use are proposals, not rules. Consent is the weak point in practice: at a UNESCO panel in Johannesburg, a speaker noted that participants may agree because they trust a doctor, not because they grasp future data use (pre-window, reported Aug 24).

Judgement for developers: data governance, not device safety, is where rules are moving. Separate data consent and limits on secondary use are the gaps named most often.

NeuralinkCompany-reported

Reported on Jan 28, 2026 zero serious device-related adverse events among 21 participants. The one documented device problem is thread retraction in the first participant (2024); signal quality rose in 18 of the next 20 participants (90%) after changes (company-reported). Data from the first three participants went to a journal, but no paper was published as of October 2026. No independent adverse-event data appear in the material.

For VOICE (NCT07224256), no peer-reviewed accuracy or latency benchmark has been published.

SynchronPeer-reviewed, context

Four early participants completed 12 months with no serious adverse event, vessel occlusion or device migration (JAMA Neurology, 2023, pre-window).

Synchron has the best-documented safety record, but that paper dates from 2023, before the window, so it is context for this quarter.

Devices and definitions differ, so the two safety records should not be ranked.

Critics citeSecondary

According to Neura Pod: Reuters' 2022 report of about 1,500 animal deaths since 2018, a June 2023 FDA inspection of the company's animal lab, results announced on X rather than in journals, and an initial absence from ClinicalTrials.gov.

Continuity of careCompany-reported

The least evidenced topic. The material contains no 2026 case of a company withdrawing support from implanted users. Neuralink's PRIME study follows each participant for about 6 years, including 5 of long-term follow-up (company brochure, via Neura Pod).

07Outlook and what to watch

Treat the quarter as infrastructure, not approval: read each route by its distance from daily use

No implanted BCI gained new market access in the window, so every route below is still investigational unless stated. This page is not medical advice and not investment advice.

How far each route is from daily use

Intracortical: still investigational, with single-participant speech evidence

Neuralink reports 21 PRIME participants (company-reported, Jan 28, 2026) and a third VOICE speech participant, with no peer-reviewed speech benchmark. Paradromics has implanted 1 of up to 10 Connect-One participants, 10% of planned enrolment (1 ÷ 10), and the FDA letter of Aug 26 widened the devices it may connect to (company-announced).

Neuralink · Jan 28, 2026 · company-reportedParadromics · Sep 14, 2026 · company press releaseFDA letter · Aug 26, 2026 · company-announced

Endovascular: a trial is recruiting, and a pivotal trial is only reported

Synchron's INTENT study plans 10 participants at 5 US sites (registry, Apr 2026). A pivotal trial is reported as planned for 2026, not confirmed by a company filing in the material.

INTENT · 10 planned · registryPivotal trial · 2026, month not stated · reported

Surface: cleared for temporary use, with further review pending

Precision's Layer 7 is cleared for up to 30 days of use, further FDA review is pending, and its Series D brought total capital to $430M (announced, Sep 24, 2026). CorTec holds two Breakthrough Device Designations, which are not approvals.

Layer 7 · up to 30 days · FDA clearance (context)CorTec · 2 designations · company-reportedPrecision · $430M total capital · announced

Ultrasound and non-invasive: licences and a first study, no decoding number

Merge Labs and Bridge Neurotech licensed Butterfly's chip, Bridge is enrolling its first human study, and neither has published a decoding number. The EEG imagined-speech baseline of 49.03 ± 4.18% is a preprint on coarse classes.

Merge Labs · Sep 1, 2026 · announcedBridge Neurotech · Oct 6, 2026 · reportedEEG baseline · week of Sep 21, 2026 · preprint

China: registered, but 13 units sold and no insurance catalogue place

Neuracle's NEO has NMPA Class III registration (Mar 13, 2026, context) but 13 units sold and no place in the insurance catalogues (reported, Sep 29, 2026 filing). Its RMB 2.5bn STAR Market application is pending against 6.175 million yuan of cumulative sales (13 × 475,000).

NEO · 13 units · reportedSTAR Market · RMB 2.5bn · filed, pendingRegistry · 21 studies, 11 implanted · Oct 19, 2026

What changed and what it implies, by reader

What changed

Speech results arrived as single-participant company demonstrations; Chinese access exists but is largely self-paid.

Implication

Treat speech claims as early evidence. In China the 475,000 yuan list price is met only partly by a supplementary scheme worth at most 142,500 yuan.

Evidence basis

Paradromics press release (Sep 14, 2026); Yahoo Tech on VOICE (Sep 16, 2026); BigGo Finance on the Sep 29, 2026 filing (reported).

What changed

The FDA letter widened investigational connectivity; designations stack up; China issued an EEG-data standard effective Sep 1, 2027.

Implication

The US gates remain designation, IDE and later review; data preparation rules are arriving in China before the standard binds.

Evidence basis

Business Wire (Aug 26, 2026, company-announced); CorTec via EQS (company-reported); TechTimes (announced).

What changed

CMS took comments on a Neuralink coding request to Oct 16; RAPID is only proposed.

Implication

A code request does not create coverage, so reimbursement lags authorisation.

Evidence basis

CMS (comments closed Oct 16, 2026, under consideration); AdvaMed (proposed).

What changed

A $250M Precision round; China leads deal count, the US capital; tracker totals run $1.63B to $4.95B.

Implication

Read tracker totals for trend only. Neuralink valuations above its $9.65B post-money round are estimates, not transactions. This is not investment advice.

Evidence basis

MedTech Dive (Sep 24, 2026, announced); New Market Pitch trackers (tracker estimates); Nasdaq Private Market per-share estimate.

What changed

A review names five gaps in implantable-BCI data protection; US neural-data definitions diverge by state.

Implication

Data consent and secondary-use limits are where rules are moving, ahead of device-safety rules.

Evidence basis

Communications Medicine (Jul 27, 2026, published); The Transmitter (Oct 16, 2026, opinion piece).

Three open items to watch

Open item 1

Whether a speech result is published with an error rate and a defined task, since none of this quarter's headline results has one.

Open item 2

Whether Synchron's pivotal trial and Precision's further FDA review are confirmed by the companies or the agency.

Open item 3

Whether Neuracle's listing proceeds against 6.175 million yuan of cumulative sales (13 × 475,000) and a 2.5bn yuan target.

Key dates

Dates already past on Oct 24, 2026 are marked Past; items with no stated day are placed at the start of their period.

Date	Event	State on Oct 24, 2026	Source
Aug 1, 2026	China's national BCI reference architecture takes effect	Past	Neurofounders
Aug 26, 2026	FDA approval letter widens Paradromics Connexus device compatibility	Past	Paradromics via Business Wire
Sep 24, 2026	Precision Neuroscience announces $250M Series D	Past	MedTech Dive
Sep 29, 2026	Neuracle updated STAR Market prospectus filed	Past	BigGo Finance
Oct 16, 2026	CMS comment deadline on Neuralink ICD-10-PCS request	Past	CMS
2026month not stated	Synchron pivotal trial reported as planned	Upcoming	Exoswan; Meticulous Research
By end-2026	Gestala plans first-generation ultrasound system and initial clinical data	Upcoming	Neurofounders
Apr 1, 2027	Requested start of the BCI insertion code	Upcoming	CMS
Sep 1, 2027	NMPA standard on EEG datasets used by AI in BCI devices takes effect	Upcoming	TechTimes; Neurofounders
2028	MIIT draft roadmap target of more than 40 BCI standards	UpcomingDraft	Neurofounders
2030	MIIT draft roadmap target of more than 80 BCI standards	UpcomingDraft	Neurofounders

→The quarter moved the field from demonstration to infrastructure: speech and durability results, money and coding requests all advanced, but none of them is an approval, a coverage decision or an independently verified outcome.